Critical Path Institute (C-Path) is thrilled to announce its Polycystic Kidney Disease Outcomes Consortium (PKDOC) has been awarded an Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD) focused Broad Agency Announcement (BAA) contract from the U.S. Food and Drug Administration (FDA).